Effects of Neuropeptide y on Stem Cells and Their Potential Applications in Disease Therapy by Peng, Song et al.
University of Wollongong
Research Online
Illawarra Health and Medical Research Institute Faculty of Science, Medicine and Health
2017
Effects of Neuropeptide y on Stem Cells and Their
Potential Applications in Disease Therapy
Song Peng
Third Military Medical University
You-Li Zhou
Third Military Medical University
Zhi-Yuan Song
Third Military Medical University
Shu Lin
University of Wollongong, Third Military Medical University
Research Online is the open access institutional repository for the University of Wollongong. For further information contact the UOW Library:
research-pubs@uow.edu.au
Publication Details
Peng, S., Zhou, Y., Song, Z. & Lin, S. (2017). Effects of Neuropeptide y on Stem Cells and Their Potential Applications in Disease
Therapy. Stem Cells International, 2017 6823917-1-6823917-12.
Effects of Neuropeptide y on Stem Cells and Their Potential Applications
in Disease Therapy
Abstract
Neuropeptide Y (NPY), a 36-amino acid peptide, is widely distributed in the central and peripheral nervous
systems and other peripheral tissues. It takes part in regulating various biological processes including food
intake, circadian rhythm, energy metabolism, and neuroendocrine secretion. Increasing evidence indicates
that NPY exerts multiple regulatory effects on stem cells. As a kind of primitive and undifferentiated cells,
stem cells have the therapeutic potential to replace damaged cells, secret paracrine molecules, promote
angiogenesis, and modulate immunity. Stem cell-based therapy has been demonstrated effective and
considered as one of the most promising treatments for specific diseases. However, several limitations still
hamper its application, such as poor survival and low differentiation and integration rates of transplanted stem
cells. The regulatory effects of NPY on stem cell survival, proliferation, and differentiation may be helpful to
overcome these limitations and facilitate the application of stem cell-based therapy. In this review, we
summarized the regulatory effects of NPY on stem cells and discussed their potential applications in disease
therapy.
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Neuropeptide Y (NPY), a 36-amino acid peptide, is widely distributed in the central and peripheral nervous systems and other
peripheral tissues. It takes part in regulating various biological processes including food intake, circadian rhythm, energy
metabolism, and neuroendocrine secretion. Increasing evidence indicates that NPY exerts multiple regulatory effects on stem
cells. As a kind of primitive and undifferentiated cells, stem cells have the therapeutic potential to replace damaged cells, secret
paracrine molecules, promote angiogenesis, and modulate immunity. Stem cell-based therapy has been demonstrated effective
and considered as one of the most promising treatments for specific diseases. However, several limitations still hamper its
application, such as poor survival and low differentiation and integration rates of transplanted stem cells. The regulatory effects
of NPY on stem cell survival, proliferation, and differentiation may be helpful to overcome these limitations and facilitate the
application of stem cell-based therapy. In this review, we summarized the regulatory effects of NPY on stem cells and discussed
their potential applications in disease therapy.
1. Introduction
NPY, a 36-amino acid neuropeptide, was first isolated by
Tatemoto et al. from swine brain in 1982 [1]; it belongs to
the pancreatic polypeptide family together with pancreatic
polypeptide (PP) and peptide YY (PYY). NPY, whose struc-
ture is characterized by a large number of tyrosine residues
(5 of 36 amino acid residues) and an amidated C-terminal
group, remained highly conserved among species in the
course of evolution [2]. As one of the most abundant neuro-
peptides, NPY is widely present in the central and peripheral
nervous systems (CNS/PNS) and is a crucial mediator for
other peripheral tissues. In the CNS, it is distributed in
regions such as the cerebral cortex, hypothalamus, brain-
stem, hippocampus, striatum, and limbic structures [2–4].
In the PNS, it is expressed in sympathetic ganglia and cost-
ored and coreleased with noradrenaline during sympathetic
nerve stimulation [5]. Mounting evidence indicates that
NPY expresses in many peripheral tissues such as the retina,
bone, adipose tissue, adrenal medulla, and platelets [6–10].
Consistent with its wide distribution, NPY has been impli-
cated in a variety of biological processes including food
intake, circadian rhythm, energy metabolism, cardiovascular
function, and neuroendocrine secretion [11–15].
Five NPY receptors (Y1, Y2, Y4, Y5, and y6) have been
identified in mammals, which all belong to the super family
of G protein-coupled receptors. However, the Y4 receptor
has limited affinity for NPY [16]. The y6 receptor is not func-
tional in primates as their y6 gene exists in a truncated ver-
sion missing the seventh transmembrane domain [17, 18].
NPY receptors are also widely distributed in central and
peripheral tissues of which each receptor exhibits different
distributions and mediates their specific functions [19].
Stem cells are a kind of primitive and undifferentiated
cells which are characterized by perpetual self-renewal and
the potency to differentiate into specialized cell types. Based
on their origin, stem cells can be categorized into two types:
embryonic stem cells (ESCs) and non-ESCs [20]. The non-
ESCs are derived from adult and fetal tissues including hema-
topoietic stem cells, bone marrow mesenchymal stem cells,
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adipose-derived stem cells, neural stem cells, and dental pulp
stem cells [21]. Stem cells have the therapeutic potential to
replace damaged cells, secrete paracrine molecules, promote
angiogenesis, modulate immunity, and facilitate tissue repair
[22, 23]. Hence, the efficacy of stem cell-based therapy has
been described in many diseases including myocardial
infarction, stroke, neuritis, liver cirrhosis, pulmonary fibro-
sis, spinal cord injuries (SCI), Parkinson’s disease, and
Alzheimer’s disease [24–31]. However, some limitations still
hamper the application of stem cell-based therapy, such as
poor survival, oncogenic potential, and low differentiation
and integration rates, which need to be further researched
to open up new avenues for the therapy.
2. Effects of NPY on Stem Cells
Increasing researches indicate that NPY exerts regulatory
effects on the proliferation, differentiation, and survival
of stem cells, which is speculated to have potential applica-
tions in treatment for many diseases. Here, we reviewed
the effects of NPY on different stem cells and the involved
mechanisms (Figure 1).
2.1. NPY and Neural Stem/Precursor Cells (NSPCs)
2.1.1. Hippocampal Precursor Cells. Howell et al. uncovered
that NPY increased the neurosphere formation of early post-
natal rat-derived primary hippocampal cultures as well as the
5-bromo-2-deoxyuridine (BrdU) incorporation of nestin+
hippocampal precursor cells, which indicated that NPY
could promote the proliferation of hippocampal precursor
cells. Besides using NPY receptor agonists and antagonists
as well as Y1 receptor knockout (Y1−/−) mice, they further
demonstrated that the proliferative effect of NPY on hippo-
campal precursor cells was mediated via Y1 receptor [32].
Subsequent study of this research group proved that NPY
displayed proliferative effect on neuronal precursors in
the dentate gyrus. There were increased total cells, neurons
(class III β-tubulin expressing cells), and cell proliferation
in postnatal rat-derived dentate gyrus cells cultured in
medium with lμM NPY than that cultured in control
medium, of which the neuroproliferative effect of NPY was
mediated by Y1 receptor and involved ERK1/2 activation.
Meanwhile, in Y1−/− mice, the proliferation rate and imma-
ture doublecortin-positive neurons in the dentate gyrus were
significantly reduced [33]. In vivo, exogenous NPY also
exhibits proliferative effect on neural progenitors in the
dentate gyrus. Decressac et al. demonstrated that intra-
cerebroventricular (ICV) injection of NPY to C57BL/6
mice promoted the proliferation of neural progenitors
and neuroblasts in the dentate gyrus, and ICV injection
of Y1 receptor agonist could mimic this proliferative effect.
However, when coinjected with Y1 receptor antagonist or
injected to Y1−/− mice, NPY could not induce the prolifer-
ation in the dentate gyrus, indicating that the proliferative
effect of NPY is mediated via Y1 receptor [34]. In short, the
mechanism involved in NPY-stimulated hippocampal pre-
cursor cell proliferation may be mediated by Y1 receptor/
intracellular nitric oxide (NO)/cyclic guanosine monopho-





















































Figure 1: Main effects of NPY on different stem cells. NPY exerts multiple regulatory effects on MSC functions, including proliferation
(via Y5R), differentiation (via Y2R and Y1R), migration, tube formation, and expression of VEGF and CXCR4. NPY could promote the
proliferation and differentiation of NSPCs through corresponding Y receptors. Meanwhile, NPY could stimulate the proliferation and
differentiation of ADSCs as well as the survival and mobilization of HSPC. In addition, exogenous NPY supports the long-term
self-renewal and proliferation of undifferentiated ESCs via the Y1 and Y5 receptors. In the figure, the NPY receptor symbols
symbolized their functional involvement in the regulation of NPY on different stem cells. NSPCs—neural stem/precursor cells;
MSCs—mesenchymal stem cells; HSPC—hematopoietic stem/progenitor cells; ADSCs—adipose-derived stem cells; ESCs—embryonic
stem cells; SVZ—subventricular zone; SCZ—subcallosal zone.
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extracellular signal-regulated kinase (ERK) 1/2 signaling
pathway [35].
In the aspect of promoting hippocampal precursor prolif-
eration, NPY is able to display synergistic action with other
proliferative factors. Rodrigo and colleagues found that the
combination of NPY and fibroblast growth factor 2 (FGF2)
more potently stimulated proliferation of nestin+ hippocam-
pal neural stem progenitor cells (NSPCs) than either factor
alone. On the one hand, NPY increased FGF receptor1
(FGFR1) mRNA and protein expression in NSPCs. On the
other hand, NPY augmented the proliferative effect of
FGF2 via Y1 receptor through shortening the cell cycle time
of NSPCs [36].
The proliferative effect of NPY on hippocampal precur-
sor cells presents not only in normal condition but also in
pathological conditions. NPY−/− mice displayed lower level
of BrdU incorporation in dentate gyrus subgranular zone
(SGZ) under the conditions of basal and kainic acid- (KA-)
induced seizure, which suggested a role for NPY in seizure-
induced proliferation of hippocampal precursor cells [37].
Baptista et al. administered the psychostimulant drug meth-
amphetamine (METH) to dentate gyrus-derived neuro-
sphere cultures and found METH decreased neuronal
differentiation of the neurosphere cultures at low concentra-
tion and induced cell death at high concentration. Besides,
NPY prevented METH-reduced neuronal differentiation
and METH-induced cell death, meanwhile NPY promoted
the proliferation of dentate gyrus-derived neurosphere
cultures [38].
2.1.2. Subventricular Zone (SVZ) Neural Precursor Cells.
Agasse et al. gave mice-derived SVZ neurosphere NPY treat-
ment and found that NPY promoted the proliferation and
neuronal differentiation of SVZ cells and, particularly, the
proneurogenic effect of NPY was mediated via Y1 receptor
and involved activation of ERK1/2 and stress-activated pro-
tein kinase (SAPK)/c-Jun-NH2-terminal kinase (JNK) sig-
naling [39]. The regulatory effects of NPY on SVZ neural
precursors were further demonstrated in vivo. Compared
with wild-type (WT) mice, there were significantly reduced
proliferating precursor cells and neuroblasts in SVZ of
Y1−/− and Y2−/− mice [40]. Researchers administrated ICV
injection of saline, NPY, Y1 receptor agonist, or a mixed solu-
tion of Y1 receptor antagonist and NPY, respectively, to adult
mice and investigated the proliferation of SVZ cells at 48 h
after injection. The results showed that NPY and Y1 receptor
agonist stimulated the proliferation of SVZ neural precursors
significantly. In contrast, the proliferative effect of NPY was
inhibited by Y1 receptor antagonist, which suggested Y1
receptor mediated this proliferative effect of NPY. Mean-
while, the researchers substantiated that NPY augmented
the migration of newly generated neuroblasts which were
formed in the SVZ toward the striatum and olfactory bulb
through rostral migratory stream [41]. Additionally, Thiriet
et al. discovered that SVZ cells produced endogenous NPY
which indicated that NPY may act as a paracrine/autocrine
factor in SVZ. They also demonstrated that NPY promoted
the proliferation and neuronal differentiation of SVZ cells,
which were isolated from newborn rats, via Y1 receptor-
mediated ERK1/2 MAP kinase pathway [42]. Accordingly,
these results indicated that NPY could promote the prolif-
eration and neuronal differentiation of SVZ neural precursor
cells via Y1 receptor; although Y2−/− mice also had reduced
proliferating precursor cells and neuroblasts in SVZ as
Y1−/− mice, the exact effects of Y2 receptor in proliferation
and differentiation of SVZ neural precursor cells were still
unclear which may be mediated by Y2 receptor itself or by
regulating Y1 receptor expression or by other mechanisms.
Further studies are needed to better understand this process.
2.1.3. Subcallosal Zone (SCZ) Precursor Cells. Unlike the
hippocampus and subventricular zone around the lateral
ventricle which regenerate neurons in mammalian adult-
hood, SCZ predominately generates oligodendrocytes. Inter-
estingly, seizure could promote the SCZ activity thereby
producing more glial progenitors which migrate to the
impaired hippocampus [43]. It has been reported that
NPY−/− mice had significantly reduced proliferative (BrdU
positive) cells in the left subcallosal zone under basal condi-
tion; meanwhile, seizure-induced proliferation in the SCZ
of NPY−/− mice also decreased compared with WT control,
which suggested that NPY played a role in the proliferation
of SCZ precursor cells [44]. Thus, it points out a significative
possibility that NPY promotes hippocampal neurogenesis
through inducing SCZ oligodendrogliogenesis.
2.1.4. Olfactory Neuronal Precursor Cells. The neuroprolifera-
tive effect of NPY was primarily identified in olfactory epithe-
lium. Hansel and colleagues uncovered that NPY−/−mice had
decreased proliferation of olfactory neuronal precursor cells
in the olfactory epithelium. They performed experiments
with primary olfactory cultures to demonstrate that NPY
facilitated the proliferation of neuronal precursor cells via
Y1 receptor and involved protein kinase C (PKC)/ERK1/2
signaling [45]. The role of NPY and Y1 receptor in prolif-
eration of olfactory precursor cells was further confirmed
in subsequent studies. Doyle et al. reported that primary
adult olfactory precursor cells derived from NPY−/−, NPY/
PYY−/−, and Y1−/− mice formed reduced olfactory neuro-
spheres compared with WT mice and only WT control-
derived glandular cells could form secondary neurospheres,
suggesting an important role of NPY signaling in prolifera-
tion of olfactory precursor cells. Furthermore, they also dis-
covered that Y1−/− mice exhibited impaired olfaction
compared withWTmice which may result from reduced for-
mation of olfactory neurons [46]. Pathological examination
of the olfactory neuroepithelium derived from NPY−/− and
WTmice revealed that there were significantly fewer number
of olfactory receptor neurons in olfactory neuroepithelium of
NPY−/− mice [47].
Furthermore, NPY is associated with neuroregeneration
of olfactory epithelium under pathological conditions. In
the olfactory epithelium, adenosine triphosphate (ATP) is
released upon injury and stimulate proliferation and differ-
entiation of olfactory neuronal precursors via P2 purinergic
receptor [48]. It has been reported that intranasal instillation
of ATP enhances the expression of NPY in olfactory epithe-
lium sustentacular and microvillous cells via P2 purinergic
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receptors and NPY stimulates the proliferation of neuronal
progenitor cells through Y1 receptor-mediated ERK1/2 acti-
vation [49, 50]. A subtype of microvillous cells which express
inositol triphosphate receptor subtype 3(IP3R3) plays a
critical role in neuroregeneration and recovery after olfac-
tory epithelium injury as they secrete sufficient NPY [51].
A recent study showed that the number of IP3R3+NPY+
microvillous cells and expression of NPY in mouse olfac-
tory epithelium existed an age-dependent decline. In addi-
tion, the number and proliferation of olfactory stem cells
also decreased with age, suggesting a role of NPY in age-
related olfactory dysfunction [52].
2.1.5. Retinal Neural Progenitor Cells. It has been reported
that NPY could promote the proliferation of retinal neu-
ral progenitor cells and retinal neural cells. The applica-
tion of exogenous NPY to primary rat retinal cell
cultures for 48h promoted retinal neural cell proliferation
significantly, and the proliferation of nestin+ retinal neural
progenitor cells in this culture was increased at the same
time. These proliferative effects of NPY are mediated via Y1,
Y2, and Y5 receptors through activation of NO-cGMP and
ERK1/2 pathway [53]. The general opinion is that the
mature mammalian retina was short of regenerative capacity
[54] but the proliferative effects of NPY on retinal neural
progenitor cells and retinal neural cells provide experi-
mental evidence and novel strategy for regeneration of
the injured retina.
2.2. NPY and Mesenchymal Stem Cells (MSCs). Wang and
colleagues found that pretreating rat bone marrow mesen-
chymal stem cells (BMSCs) with NPY for 72 h upregulated
the expression of vascular endothelial growth factor (VEGF)
and genes required for mitosis, including aurora B kinase,
FGF-2, cyclin A2, eukaryotic initiation factor 4E, and stromal
cell-derived factor-1α, when under hypoxia condition.
Meanwhile, NPY pretreatment promoted the migration of
BMSCs through upregulating CXCR4 expression and
induced endothelium differentiation as well as tube forma-
tion of BMSCs [55]. It has been reported that NPY enhanced
the proliferation of rat bone marrow stromal cells (BMCs)
which was mediated via Y5 receptor. The proliferative
response to NPY of BMCs isolated from old rats is weaker
than those isolated from neonatal and young rats, because
of the decreased expression of Y5 receptors in old BMCs.
Furthermore, Y5 receptor gene transfection restored the
impaired growth potential of old BMCs [56].
Recent studies have demonstrated that NPY system
displays regulatory effects on osteoblastic and adipogenic
differentiation of MSCs. Compared with wild-type control,
BMCs derived from Y2−/− mice cultured under osteogenic
and adipogenic conditions exhibited increased mineraliza-
tion and adipocyte formation, respectively [57]. The Y1
receptor mRNA expression of BMCs cultured from Y2−/−
mice was downregulated, which maybe a result from the
lack of Y2 receptor signaling relieved the feedback inhibition
on NPY release, and elevated NPY caused overstimulation of
Y1 receptors and followed by desensitization and downregu-
lation of Y1 receptor [57]. In a follow-up study, Lee et al.
reported that BMCs from Y1−/− mice formed more miner-
alized nodules under osteogenic conditions and more
adipocytes under adipogenic conditions, compared with
wild-type control. Meanwhile, the MSCs and mesenchymal
osteoprogenitor cells isolated from the bone of Y1−/− mice
have enhanced ability to differentiate into osteoblasts and
adipocytes, which indicated that NPY could suppress the
differentiation of mesenchymal progenitor cells via Y1
receptor [58]. Besides, previous research showed that exog-
enous NPY promoted osteoblast differentiation of primary
mouse BMCs through Y2 receptor [59]. However, Liu and
colleagues discovered that NPY enhanced osteoblastic dif-
ferentiation of rat BMSCs in a concentration-dependent
manner via Y1 receptor and Wnt signaling pathway [60].
Recent study indicated that NPY promoted the osteogenic
differentiation of health volunteer-derived BMSCs and
increased the expression of Y1 receptor in human BMSCs
[61]. In view of these serial researches, we concluded that in
mice, NPY could promote the osteoblastic differentiation of
MSCs via Y2 receptor and inhibit MSCs differentiating into
osteoblasts via Y1 receptor. Moreover, Y2 receptor exhibited
dual feedback inhibition on MSC osteoblastic differentiation
through feedback inhibition on NPY release, thereby regu-
lating the expression level of Y1 receptor. However, in rats
and human, it has been reported that NPY promoted the
osteoblastic differentiation of MSCs through Y1 receptor.
These conflicting results in different species need to be
further investigated.
2.3. NPY and Hematopoietic Stem/Progenitor Cells (HSPC). It
was reported that NPY was of great importance in the sur-
vival and mobilization of HSPC. Park et al. uncovered that
there were reduced hematopoietic stem cells (HSCs) in the
bone marrow of NPY−/− mice and these mice had fewer
SNS fibers and CD31+ ECs in bone marrow. Through inves-
tigating the cause and effect relationships, they concluded
that NPY deficiency caused p53-dependent apoptosis of
SNS fibers and/or CD31+ ECs in the bone marrow, resulting
in impairment of HSC survival. Further pharmacological
experiments of NPY increase and Y1 receptor intervention
illustrated that NPY/Y1 receptor regulation affected HSC
survival by reducing apoptosis of SNS fibers and ECs in
marrow microenvironment [62]. As a recent study showed,
compared with WT control, the HSPC mobilization in
NPY−/− mice was impaired which resulted from the
decreased matrix metalloproteinase-9 (MMP-9) activity in
bone marrow-induced upregulation of HSPC maintenance
factors. Besides, exogenous NPY or elevation of endogenous
NPY by stress stimulated MMP-9 activity of osteoblast via
Y1 receptor thereby suppressing HSPC maintenance factors
and inducing HSPC mobilization in mice [63]. Hence, these
stimulatory effects of NPY on survival and mobilization of
HSPC were mediated through regulating hematopoietic
stem cell niche. The HSC niche is critical to support HSC
function and to maintain a proper balance between self-
renewal and multilineage differentiation. Various types of
cells have been identified as HSC niche components which
include osteoblasts, stromal cells, vascular endothelial cells,
macrophages, adipocytes, and megakaryocytes [64, 65].
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Not only osteoblasts that was mentioned above but also
vascular endothelial cells, macrophages, and adipocytes
have been identified to be regulated by NPY [62, 66, 67],
which indicated the potential that NPY could regulate the
function of HSPC via these HSC niche component cells.
Additionally, previous studies showed that NPY is expressed
by bone marrow hematopoietic cells [62, 68] which indicated
that HSPC may exert feedback regulation on HSC niche via
releasing NPY.
2.4. NPY and Adipose-Derived Stem Cells (ADSCs). Wu et al.
researched the effects of NPY at different concentrations
on proliferation and differentiation of cultured human
adipose-derived stem cells (hADSCs). The results revealed
that NPY stimulated the proliferation of hADSCs at low
concentrations (10−14–10−11mol/L), however, at high con-
centrations (10−10–10−6mol/L), NPY inhibited the prolifera-
tion and promoted adipogenic differentiation of hADSCs
[69]. Yang et al. uncovered that rat primary preadipocytes
and 3T3-L1 cells (a murine preadipocyte cell line) expressed
abundant Y1 receptors, and at the same time, NPY promoted
the proliferation of rat primary preadipocytes and 3T3-L1
cells in a concentration-dependent manner via Y1 receptor
and related to the ERK1/2 pathway [70]. Meanwhile, it
was reported that visceral adipose tissue [70] and abdominal
subcutaneous adipose tissue [71] synthesized NPY, which
indicated that adipose tissue may release NPY in an autocrine
manner thereby promoting the proliferation and adipogenic
differentiation of its resident ADSCs and adipocyte precursor
cells, and consequently result in the further accumulation of
the adipose tissue.
2.5. NPY and Embryonic Stem Cells (ESCs). Son and col-
leagues uncovered that undifferentiated human ESCs
expressed NPY, Y1, and Y5 receptors and exogenous NPY
supported the long-term self-renewal and proliferation of
undifferentiated human ESCs via the Y1 and Y5 receptors
involving the activation of AKT, ERK1/2, and cAMP-
response element-binding (CREB) signaling [72]. Based on
the regulatory effect of NPY on human ESC self-renewal, this
group designed a novel chemically defined medium with
NPY supplement which could support the long-term culture
of human ESCs without feeder cells and serum [72]. The
traditional ESC culture needs the support of inactivated
mouse embryo fibroblast and fetal calf serum. However, the
indeterminacy of feeder cell secretion and potential pathogen
contamination of serum hinder the research and application
of ESCs. The development of a xeno-free and serum-free
medium that supports the long-term culture derivation and
large-scale propagation is still one of the major challenges
for the clinical application of ESCs. Therefore, the chemically
defined medium with NPY supplement may become a novel
strategy for ESC translational research. Additionally, NPY
takes part in stress-induced adipogenesis of ESCs. As a study
showed, stress hormone epinephrine (EPI) facilitated the
expression of NPY, Y1, and Y2 receptors in murine ESCs,
of which EPI enhanced the adipogenic differentiation of
murine ESCs via the NPY system [73].
3. Potential Application of NPY’s Regulatory
Effects on Stem Cells
3.1. Neurodegenerative Diseases. Neurodegenerative diseases
are a group of disorders originating from the degeneration
of central neurons that gradually leads to cognitive and/or
motor dysfunctions [74]. These disorders include Alzhei-
mer’s disease (AD), Parkinson’s disease (PD), Huntington’s
disease (HD), multiple sclerosis (MS), and Machado-Joseph
disease (MJD). With an increase in lifespan, the prevalence
of neurodegenerative diseases is increasing significantly
[75]. To date, there are no effective treatments for neurode-
generative diseases and the available clinical therapies mainly
help in keeping patients from getting worse for a limited
period of time [76, 77].
In recent years, the effects of NPY on neurodegenerative
diseases and the involved mechanisms have been revealed
gradually. Just as reported previously, NPY inhibited the
phagocytosis, inflammatory factor release, and motility of
activated microglial cells, thereby attenuating microglia-
mediated inflammation in injury area of the CNS [78–80].
Aveleira et al. demonstrated that NPY stimulated autoph-
agy of neural cells in in vitro and in vivo experiments,
indicating that NPY could promote the clearance of mis-
folded and abnormal proteins that caused neurodegenera-
tive diseases through autophagy [81]. Excitotoxicity and
alteration in calcium homeostasis are related to neurode-
generative diseases. Some studies suggested that NPY
reduced glutamate-mediated excitotoxicity and regulated
calcium homeostasis [82–85]. Besides, NPY displays some
ameliorative effects on clinical manifestations of neurode-
generative diseases. Researchers have investigated the anti-
depressive effects of NPY in rodent forced swim test, and
the results revealed that NPY exerted antidepressant-like
properties via Y1 receptor [86–88]. As an orexigenic agent,
NPY may ameliorate the weight loss in neurodegenerative
diseases [89].
The main physiopathological feature of neurodegenera-
tive diseases is progressive degeneration of neurons; hence,
neuronal replacement is considered as a promising thera-
peutic strategy for neurodegenerative diseases [90]. Recently,
an increasing number of studies have demonstrated the
regulatory effects of NPY on neuronal precursor cells. NPY
facilitates the proliferation of hippocampal precursor cells
[32, 33] via Y1-receptor-mediated intracellular NO/cGMP/
PKG/ERK1/2 pathway [35]. NPY also promoted the prolifer-
ation and neuronal differentiation of SVZ neural precursors
[39, 42], as well as the migration of newly formed neuroblast
toward striatum and olfactory bulb [41]. The hippocampus
and SVZ are the most active areas of neurogenesis in adult
brain, and the stimulative effects of NPY on neural precursor
proliferation and differentiation in these regions are likely
to ameliorate neuron loss in neurodegenerative diseases.
Decressac et al. administrated a single ICV injection of
NPY to R6/2 mice (a transgenic model of Huntington’s
disease) and found that NPY improved motor function
and extended survival time of the R6/2 mice through
reduced body weight loss, meanwhile, NPY promoted cell
proliferation and neuroblasts generation in the SVZ of
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R6/2 mice [91]. In a hippocampal neurodegeneration rat
model induced by trimethyltin (TMT), ICV injection of
NPY decreased TMT-induced hippocampal damage and
stimulated hippocampal neurogenesis through the upregu-
lation of BDNF, Bcl2l1, Bcl-2, Sox-2, Noggin, NeuroD1,
and doublecortin genes [92], and the increased newly born
neurons later integrated into the local hippocampal cir-
cuits [93]. Researchers gave APP-transgenic (tg) mouse
(a mouse model of Alzheimer’s disease) CNS-targeted
delivery of NPY, and they discovered that NPY treatment
ameliorated behavioral deficits as well as neurodegenera-
tive pathology of APP-tg mouse and promoted the prolif-
eration of neural precursor cells in subgranular zone of the
APP-tg mouse [94].
3.2. Retinal Degenerative Diseases. Retinal degenerative
diseases, such as age-related macular degeneration, retinopa-
thies, and glaucoma, are a group of ocular diseases charac-
terized by chronic neuronal loss. Currently, there is no
cure for retinal degenerative diseases, the main causes of
vision loss and blindness. The therapeutic potential of
NPY in retinal degenerative diseases has been appreciated
due to its neuroprotection and proliferative effect on retinal
neural progenitor cells.
It has been shown that exogenous NPY inhibited
3,4-methylenedioxymethamphetamine- (MDMA-) induced
necrosis and apoptosis in rat retinal neural cell cultures
[95]. Meanwhile, NPY has protective effects against gluta-
mate and N-methyl-D-aspartic acid- (NMDA-) induced
rat retinal cell death [83, 96]. NPY could inhibit intracel-
lular calcium concentration ([Ca2+]i) changes in cultured
rat retinal neurons through Y1,Y4, and Y5 receptors
[97], which may be one of the mechanisms for the neuro-
protective effect of NPY. Furthermore, NPY could inhibit
osmotic swelling of Müller cells via Y1 receptor [98, 99],
and this glial volume regulatory effect of NPY may be related
to its retinal neuroprotection.
Stem cell-based therapy is a novel and promising treat-
ment strategy for retinal degenerative diseases [100]. As
mentioned above, NPY promotes the proliferation of retinal
neural progenitor cells in primary rat retinal cell cultures
[53]. Müller glial cells were identified as a candidate for
endogenous retinal stem cells which could differentiate into
certain retinal cell types [101–103]. NPY exerts biphasic
modulatory effect on proliferation of Müller glial cells. It
reduced the proliferation of Müller cells at low concentration,
while at higher concentration, it promoted proliferation
[104]. Thus, the proliferative effects of NPY on retinal
stem/progenitor cells indicate that NPY is a putative target
for retina regeneration.
3.3. Myocardial Infarction. Stem cell therapy is a promising
approach for myocardial infarction (MI) via replenishing
cell loss and supplying cytokines that induce angiogenesis
or activate resident cardiac stem cell migration and com-
mitment to cardiomyocytes [105]. Some major challenges
still plague the stem cell therapy for MI, such as low cell
survival rate and poor engraftment of the transplanted
cells; therefore, new strategies are desired for better
therapeutic effects in stem cell transplantation [106].
The multiple effects of NPY on stem cells, cardiomyo-
cytes, and angiogenesis may be useful in stem cell-based
therapy for MI.
It has been shown that NPY pretreatment upregulated
the expression of VEGF and mitosis-related genes of rat
BMSCs and promoted the migration, endothelium differ-
entiation, and tube formation of BMSCs [55]. Researchers
transplanted NPY-pretreated or NPY-untreated BMSCs
into the ischemic ventricular wall of myocardial infarcted
rats. Four weeks later, they uncovered that NPY pretreatment
induced BMSCs to differentiate into cardiomyocytes and
endothelium cells in the infarcted myocardium and myocar-
dial infarcted rats which received NPY-pretreated BMSCs
exhibited improved cardiac function and reduced ventricular
remodeling and fibrosis than those which received untreated
BMSCs [55].
In a swine model of chronic myocardial ischemia,
NPY treatment improved left ventricular function and
enhanced angiogenesis and arteriogenesis via stimulating
proangiogenic receptor, growth factor expression, and
decreasing antiangiogenic protein expression [107]. In
follow-up studies, researchers applying a swine model of
hypercholesterolemia and chronic myocardial ischemia
demonstrated that local infiltration of NPY in ischemic
myocardial improved collateral vessel formation, blood
flow, and myocardial function [108], as well as decreased
cardiomyocytes apoptosis and myocardium fibrosis in the
ischemic region [109]. Furthermore, in vitro experiments
revealed that NPY directly induced neonatal and adult
rat cardiomyocytes cell cycle reentry and promoted their
mitosis and cytokinesis [55]. Thus, given the regulatory
effects of NPY on stem cell and the multifaceted beneficial
effects on ischemic myocardium, it can be speculated that
a combined treatment of stem cells with NPY may be a
novel strategy for ischemic heart disease including myo-
cardial infarction.
3.4. Osteoporosis. In recent years, the regulatory effects of
NPY on osteogenesis and the involved mechanisms have
been revealed, which suggested that NPY could be a novel
therapeutic target for osteoporosis. Lee and colleagues
reported that NPY system inhibited osteoblastic differentia-
tion of mesenchymal progenitor cells and mineralization of
mature osteoblasts via the Y1 receptor [58]. Researchers gave
C57/BLmice oral administration of BIBO3304 (a selective Y1
receptor antagonist) for 8 weeks and found that this Y1
receptor antagonist increased bone mass of mice in a dose-
dependent manner and without adverse extraskeletal side
effects [110]. Besides, Liu et al. performing experiments with
rat primary BMSCs discovered that NPY stimulated osteo-
blastic differentiation of BMSCs via activating Wnt signaling
pathway [60]. In addition, the promotion of NPY on human
BMSC osteogenic differentiation has been demonstrated in
in vitro experiments [61]. Although it has not been
reported, we can speculate that the regulation of NPY on
the osteogenic differentiation of BMSCs may play a role
in the treatment of osteoporosis. As recent studies showed,
NPY also affected bone homeostasis through regulating
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hematopoietic stem/progenitor cell (HSPC) mobilization.
Park and colleagues demonstrated that NPY induced
HSPC mobilization by decreasing HSPC maintenance fac-
tor expression via activating matrix metalloproteinase-9 in
osteoblasts [63]. And in a mouse model of ovariectomy-
induced osteoporosis, NPY treatment ameliorated bone
loss by decreasing the number of osteoclasts via increased
HSPC mobilization [63]. In subsequent study, this group
constructed two NPY-based peptides which were recom-
bined from the cleavage of NPY. These new NPY peptides
reduced bone loss in ovariectomized mice more effectively
than the full-length NPY, suggesting their potential appli-
cation in osteoporosis [111].
Furthermore, NPY system still regulates bone homeosta-
sis at the CNS level. In wild-type mice, overexpression of
hypothalamus NPY resulted in decrease of osteoblast activity
[112]. When Y2 receptor was hypothalamus specific deleted
in mice, there was a marked increase in the cancellous and
cortical bone volume [113]. The y6R in suprachiasmatic
nucleus is required for maintenance of bone mass in mice
as it stimulates bone formation and suppresses bone resorp-
tion [114]. In general, NPY system exerts multiple regulatory
effects on bone homeostasis at CNS and peripheral levels,
suggesting that regulating NPY activity may be a novel strat-
egy for osteoporosis treatment.
3.5. Obesity. NPY has been demonstrated to have critical
effects on the development of obesity through promoting
appetite and decreasing energy expenditure [115–117].
Additionally, NPY could directly regulate adipogenesis in
peripheral tissues. NPY stimulates the proliferation of
hADSCs at low concentration and promotes its adipogenic
differentiation at high concentration [69]. The ability of
mouse bone marrow stromal cells to differentiate into adipo-
cytes was enhanced in the absence of Y1 receptor [58]. NPY
also facilitates the proliferation of rat primary preadipocytes
and 3T3-L1 preadipocytes in a concentration-dependent
manner via Y1 receptor-mediated activation of ERK1/2 sig-
naling pathway [70] and facilitates adipogenic differentiation
of 3T3-L1 preadipocytes via Y2 receptor [71]. In vivo,
administration of a NPY pellet in subcutaneous abdominal
fat of mice increased the weight and volume of adipose tissue,
illustrating the ability of NPY to locally stimulate adipogene-




















































Figure 2: Potential application of NPY’s regulatory effects on stem cells. Animal experiments have demonstrated the potential to utilize
the regulatory effects of NPY on stem cells for disease treatment (solid violet arrow). Meanwhile, some potential applications could be
hypothesized (dotted violet arrow). Besides, given the beneficial effects of NPY itself on these diseases (solid green arrow), combined use
of stem cells with NPY may be a novel treatment strategy. NPY—neuropeptide Y; NSPC—neural stem/precursor cell; MSC—mesenchymal
stem cell; HSPC—hematopoietic stem/progenitor cells; ADSC—adipose-derived stem cell; CNS—central nervous system.
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the NPY system in peripheral tissue may facilitate interven-
tion for obesity.
4. Conclusions
In summary, NPY exerts multiple regulatory effects on
stem cell activities including proliferation, differentiation,
self-renewal, factor secretion, migration, and mobilization.
NPY could be applied as an adjunct for stem cell grafting
and facilitate tissue regeneration as appropriate. Existing
data provide evidence that there are potential applications
of NPY’s regulatory effects on stem cells in treatment of
some important diseases (Figure 2). However, it is still
in its infancy. The knowledge about effects of NPY on
ESCs, HSPC, and induced pluripotent stem cells (iPSCs)
are still limited. Further studies are needed to unravel
the effects and mechanisms of NPY on different kinds of
stem cells, as well as the efficiency and safety in the stem
cell-based therapy.
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